Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 20979472.
- Also identified by DOI 10.1056/NEJMoa1007056 and PMC identifier 3014292.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. Approximately half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression. We report a sustained partial response to the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with ALK-translocated IMT, as compared with no observed activity in another patient without the ALK translocation. These results support the dependence of ALK-rearranged tumors on ALK-mediated signaling and suggest a therapeutic strategy for genomically identified patients with the aggressive form of this soft-tissue tumor. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).
Medical subject headings
- Abdominal Neoplasms
- Granuloma, Plasma Cell
- Neoplasms, Muscle Tissue
- Protein Kinase Inhibitors
- Protein-Tyrosine Kinases
- Pyrazoles
- Pyridines